Figure 3. . Iron is targeted to GD2⁺ neuroblastoma cells after anti-GD2-Bionized NanoFerrite treatment.

(A) Ferrozine spectrophotometry shows increase in Fe²⁺/Fe³⁺ in GD2⁺ cells after anti-GD2-BNF (aGD2-BNF) treatment when compared with basal iron levels. Averages ± standard error of three to five experiments per cell line (**p = 0.01). (B) Ferrozine spectrophotometry shows pretreatment of CHLA-20 cells with free hu14.18K322A anti-GD2 antibody (aGD2) prevents cell loading with iron during anti-GD2-BNF treatment. Averages ± standard error of four experiments (*p ≤ 0.04; **p = 0.01). (C) Microscopy of Perls staining of nonheme iron in CHLA-20 cells after treatment with untargeted BNF, targeted anti-GD2-BNF and free hu14.18K322A anti-GD2 antibody (aGD2) pretreatment before anti-GD2-BNF. Representative of five repeats, 200×.

BNF: Bionized NanoFerrite.